Fusion Antibodies (LON:FAB) Shares Up 12.2% on Insider Buying Activity

Fusion Antibodies plc (LON:FAB) was up 12.2% during trading on Wednesday following insider buying activity. The company traded as high as GBX 4.80 ($0.06) and last traded at GBX 4.66 ($0.06). Approximately 1,225,806 shares traded hands during mid-day trading, an increase of 10% from the average daily volume of 1,114,868 shares. The stock had previously closed at GBX 4.15 ($0.05).

Specifically, insider Adrian Kinkaid acquired 83,728 shares of Fusion Antibodies stock in a transaction on Wednesday, October 16th. The stock was purchased at an average cost of GBX 4 ($0.05) per share, with a total value of £3,349.12 ($4,373.36).

Fusion Antibodies Trading Up 15.7 %

The business’s 50 day moving average price is GBX 3.61 and its 200-day moving average price is GBX 3.51. The company has a current ratio of 3.87, a quick ratio of 2.36 and a debt-to-equity ratio of 2.40. The company has a market cap of £4.58 million, a price-to-earnings ratio of -120.00 and a beta of 0.49.

Fusion Antibodies Company Profile

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.